Xiamen Amoytop Biotech Valuation
Is 688278 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 688278 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 688278 (CN¥71.69) is trading below our estimate of fair value (CN¥96.81)
Significantly Below Fair Value: 688278 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 688278?
Key metric: As 688278 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 688278's PE Ratio? | |
|---|---|
| PE Ratio | 39.4x |
| Earnings | CN¥740.69m |
| Market Cap | CN¥29.16b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11x |
| Enterprise Value/EBITDA | 31.4x |
| PEG Ratio | 1.2x |
Price to Earnings Ratio vs Peers
How does 688278's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 33.2x | ||
301301 Yili Chuanning BiotechnologyLtd | 20.7x | 14.9% | CN¥28.5b |
688363 Bloomage BioTechnology | 62.5x | 34.7% | CN¥27.5b |
002252 Shanghai RAAS Blood Products | 26.9x | 17.0% | CN¥49.2b |
002007 Hualan Biological Engineering | 22.8x | 18.7% | CN¥30.5b |
688278 Xiamen Amoytop Biotech | 39.4x | 32.0% | CN¥29.2b |
Price-To-Earnings vs Peers: 688278 is expensive based on its Price-To-Earnings Ratio (39.4x) compared to the peer average (33.2x).
Price to Earnings Ratio vs Industry
How does 688278's PE Ratio compare vs other companies in the CN Biotechs Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 688278 is expensive based on its Price-To-Earnings Ratio (39.4x) compared to the CN Biotechs industry average (35.5x).
Price to Earnings Ratio vs Fair Ratio
What is 688278's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 39.4x |
| Fair PE Ratio | 36.1x |
Price-To-Earnings vs Fair Ratio: 688278 is expensive based on its Price-To-Earnings Ratio (39.4x) compared to the estimated Fair Price-To-Earnings Ratio (36.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥71.69 | CN¥85.76 +19.6% | 11.4% | CN¥95.52 | CN¥76.00 | n/a | 2 |
| Nov ’25 | CN¥78.39 | CN¥85.76 +9.4% | 11.4% | CN¥95.52 | CN¥76.00 | n/a | 2 |
| Oct ’25 | CN¥71.65 | CN¥82.60 +15.3% | 8.0% | CN¥89.20 | CN¥76.00 | n/a | 2 |
| Sep ’25 | CN¥55.84 | CN¥82.60 +47.9% | 8.0% | CN¥89.20 | CN¥76.00 | n/a | 2 |
| Aug ’25 | CN¥47.90 | CN¥86.10 +79.7% | 3.6% | CN¥89.20 | CN¥83.00 | n/a | 2 |
| Jul ’25 | CN¥52.90 | CN¥86.10 +62.8% | 3.6% | CN¥89.20 | CN¥83.00 | n/a | 2 |
| Jun ’25 | CN¥54.65 | CN¥86.10 +57.5% | 3.6% | CN¥89.20 | CN¥83.00 | n/a | 2 |
| May ’25 | CN¥60.51 | CN¥86.10 +42.3% | 3.6% | CN¥89.20 | CN¥83.00 | n/a | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Jiangsu Kanion PharmaceuticalLtd
CN¥8.1b
Researches and develops, produces, and sells Chinese medicines.
600557
CN¥14.29
7D
-4.2%
1Y
-23.6%
China Resources Double-Crane PharmaceuticalLtd
CN¥21.4b
China Resources Double-Crane Pharmaceutical Co.,Ltd.
600062
CN¥20.80
7D
-3.9%
1Y
12.1%
Hunan Jiudian Pharmaceutical
CN¥11.5b
Researches, develops, produces, and sells pharmaceutical products in China and internationally.
300705
CN¥23.19
7D
-2.6%
1Y
13.6%